U.S. Banks Stock News

NasdaqGM:LNTH
NasdaqGM:LNTHMedical Equipment

Assessing Lantheus Holdings (LNTH) Valuation After Recent Share Price Momentum

Event context and recent performance Lantheus Holdings (LNTH) has drawn fresh attention after its recent trading performance, with the stock up about 3% over the past week, 8% over the past month, and 13% in the past 3 months. See our latest analysis for Lantheus Holdings. At a share price of $78.08, Lantheus has seen short term momentum build with a 30 day share price return of 7.61% and year to date share price return of 16.07%. However, the 1 year total shareholder return of 16.41% and 3...
NasdaqGS:ASO
NasdaqGS:ASOSpecialty Retail

Is It Time To Reassess Academy Sports and Outdoors (ASO) After Its Strong 1 Year Rally?

If you are wondering whether Academy Sports and Outdoors is attractively priced right now, the stock's recent track record and current valuation metrics offer a useful starting point for your own view. The share price closed at US$57.18 recently, with returns of 1.3% over 7 days, a 5.1% decline over 30 days, 9.6% year to date, 69.5% over 1 year, a 11.0% decline over 3 years, and 86.9% over 5 years. This gives you a range of outcomes to weigh. Recent coverage of Academy Sports and Outdoors...
NasdaqGS:CACC
NasdaqGS:CACCConsumer Finance

Is Credit Acceptance (CACC) Price Justified After Recent Share Rebound And Mixed Valuation Signals

If you are trying to work out whether Credit Acceptance at around US$444 per share looks expensive or offers value, the starting point is understanding what the current share price actually reflects. Over the last week the stock is up 5.0%, while the 1 year return sits at a 5.0% decline and the year to date move is a 2.0% decline, which hints that sentiment around risk and reward has shifted more than once recently. The share price moves sit against a backdrop of ongoing attention on...
NYSE:SPCE
NYSE:SPCEAerospace & Defense

Assessing Virgin Galactic (SPCE) Valuation After Fresh Analyst Outlooks And 2025 Financial Results

Why Virgin Galactic’s latest filings and results are drawing attention Virgin Galactic Holdings (SPCE) has come back into focus after its fourth quarter and full year 2025 results, alongside a new shelf registration for common stock tied to an employee stock ownership plan. The company reported fourth quarter 2025 sales of US$0.312 million and a net loss of US$62.72 million, with full year sales of US$1.54 million and a net loss of US$278.91 million, prompting fresh interest in its capital...
NYSE:WCC
NYSE:WCCTrade Distributors

Is It Too Late To Consider WESCO International (WCC) After A 111% One-Year Surge?

If you are wondering whether WESCO International's share price still offers value, or if the easier gains have already been made, this article breaks down what the current price might be implying. The stock most recently closed at US$278.57, with returns of 1.8% over 7 days, 5.5% over 30 days, 10.5% year to date, 111.4% over 1 year, 110.0% over 3 years, and 232.4% over 5 years. Recent market attention around WESCO International has focused on its role as a key distributor in capital goods...
NYSE:LMT
NYSE:LMTAerospace & Defense

Will Artemis II’s Orion Success and Missile Expansion Rebalance Lockheed Martin’s (LMT) Space Defense Narrative?

In early April 2026, NASA’s Orion spacecraft, built by Lockheed Martin, successfully launched the crewed Artemis II mission from Kennedy Space Center, carrying four astronauts on a 10-day journey around Earth and beyond the far side of the Moon with upgraded life support, controls, and safety systems. This mission highlights how Lockheed Martin’s space technology work sits alongside its expanding missile and aircraft programs, underscoring its role across both deep-space exploration and...
NYSE:CWEN.A
NYSE:CWEN.ARenewable Energy

Is It Too Late To Consider Clearway Energy (CWEN.A) After Its Strong Share Price Run?

If you are wondering whether Clearway Energy's share price still offers value after a strong run, the key is understanding what the current market price might already be factoring in. The stock last closed at US$39.64, with returns of 1.2% over 7 days, 12.7% over 30 days, 23.4% year to date, 68.3% over 1 year, 58.3% over 3 years and 94.3% over 5 years. This raises the question of how much of the story is already reflected in the valuation. Recent news around Clearway Energy has focused on...
NasdaqGS:SFM
NasdaqGS:SFMConsumer Retailing

Is It Time To Revisit Sprouts Farmers Market (SFM) After Recent Share Price Pullback

Investors may be wondering whether Sprouts Farmers Market is still priced attractively after recent volatility, or if the easy value has already been taken off the table. The stock closed at US$77.12, with returns of 0% over 7 days, a 3.9% decline over 30 days, a 4.4% decline year to date, a 46.7% decline over 1 year, but gains of 123.9% over 3 years and 182.9% over 5 years. Recent attention on Sprouts Farmers Market has focused on its longer term share price track record compared with more...
NasdaqCM:WSC
NasdaqCM:WSCConstruction

Why WillScot Holdings (WSC) Is Up 5.1% After Fleet Write-Offs And EBITDA Decline And What's Next

In its latest results, WillScot Holdings reported a 13% year-over-year decline in EBITDA, a similar drop in units on rent, and wrote off about 15% of its rental fleet, underscoring mounting financial and operational pressure. These fleet impairments and signs of tougher competition, particularly from United Rentals, point to a business mix tilting toward smaller, less profitable segments. Against this backdrop of fleet write-offs and weakening core metrics, we will assess how the news...
NYSE:BNT
NYSE:BNTInsurance

A Look At Brookfield Wealth Solutions (BNT) Valuation As Recent Returns Turn Mixed

Why Brookfield Wealth Solutions is on investors’ radar today Brookfield Wealth Solutions (BNT) has been drawing attention after a period where the share price shows mixed returns across different time frames. This has prompted closer scrutiny of its business mix and current valuation. See our latest analysis for Brookfield Wealth Solutions. The latest 1 day share price return of a 0.4% decline and 90 day share price return of a 12% decline contrast with a 1 year total shareholder return of...
NasdaqGS:LNT
NasdaqGS:LNTElectric Utilities

How Investors Are Reacting To Alliant Energy (LNT) AI Data Center Pivot And US$1 Billion Equity Raise

In recent weeks, Alliant Energy announced a US$1.00 billion at-the-market equity offering to fund data center and AI/cloud-related infrastructure, alongside governance changes such as a mandatory director retirement age of 70 and a target of 75% independent board representation. The same initiatives have drawn rising environmental and community opposition in Wisconsin and Iowa, highlighting that Alliant’s push into digital infrastructure could reshape both its growth profile and its...
NasdaqGS:RARE
NasdaqGS:RAREBiotechs

A Look At Ultragenyx Pharmaceutical (RARE) Valuation After FDA Acceptance Of UX111 Resubmitted BLA

Ultragenyx Pharmaceutical (RARE) is back in focus after the FDA accepted its resubmitted biologics license application for UX111, a gene therapy for Sanfilippo syndrome Type A, with an accelerated approval decision expected later this year. See our latest analysis for Ultragenyx Pharmaceutical. The FDA milestones around UX111 and UX016 have arrived against a mixed backdrop, with a sharp 18.5% 7 day share price return contrasting with a 1 year total shareholder return of 28.84% and a 5 year...
NYSE:CTVA
NYSE:CTVAChemicals

What Corteva (CTVA)'s Bullish Analyst Wave and New High Means For Shareholders

Corteva recently reached a new all-time high, supported by overwhelmingly positive analyst sentiment that now skews toward “Buy” ratings from major firms. Low short interest and strong participation from both Wall Street and individual investors highlight how sentiment alone can materially influence Corteva’s trading activity. We’ll now explore how this wave of bullish analyst support could reshape Corteva’s investment narrative and perceived risk-reward balance. This technology could...
NYSE:GRBK
NYSE:GRBKConsumer Durables

A Look At Green Brick Partners (GRBK) Valuation After The Rainwater Crossing Master Planned Community Announcement

Green Brick Partners (GRBK) is drawing fresh investor attention after announcing Rainwater Crossing, a master planned community in Celina, Texas that combines new model homes, multiple builders, extensive amenities and public art. See our latest analysis for Green Brick Partners. Alongside the Rainwater Crossing announcement, Green Brick Partners’ share price has moved to US$66.26, with a 7 day share price return of 5.59% but a 30 day share price return of a 3.00% decline. The 1 year total...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Is It Too Late To Consider Vera Therapeutics (VERA) After Its Recent Share Price Surge?

Wondering whether Vera Therapeutics at around US$40.45 is still offering value, or if the easy gains are behind it? This article is designed to help you frame that question clearly. The stock has returned 6.2% over the last week and 3.5% over the last month, while year to date it is down 16.8% but up 102.8% over the past year and a very large amount over three years. This naturally raises questions about what is already priced in. Recent coverage has focused on Vera Therapeutics as investors...
NasdaqGS:ALGN
NasdaqGS:ALGNMedical Equipment

A Look At Align Technology (ALGN) Valuation After Earnings Beats And Analyst Upgrades

Align Technology (ALGN) is back in focus after a run of analyst upgrades tied to its recent earnings performance, with revenue and net income both showing year over year growth and valuation metrics attracting fresh investor attention. See our latest analysis for Align Technology. At a share price of US$171.87, Align’s recent 7 day share price return of 3.37% and year to date share price return of 10.15% sit against a 1 year total shareholder return of 12.08%, while the 3 year and 5 year...
NasdaqGS:GH
NasdaqGS:GHHealthcare

Should Guardant Health’s (GH) Role in ENHERTU’s Japan Approval Require Action From Investors?

In late March 2026, Guardant Health announced that its InfinityAI real-world evidence platform was used alongside clinical trial data to support Japan’s approval of Daiichi Sankyo’s ENHERTU for treating HER2-positive advanced or recurrent solid cancers refractory or intolerant to standard therapies. This use of InfinityAI highlights how Guardant’s clinicogenomic data and artificial intelligence can help regulators assess outcomes in genomic subpopulations that are difficult to enroll in...
NasdaqCM:CELC
NasdaqCM:CELCBiotechs

Why Celcuity (CELC) Is Up 5.5% After Reporting Wider 2025 Losses From Ongoing R&D Spending

Celcuity Inc. recently reported fourth-quarter 2025 results showing a net loss of US$50.97 million, with basic loss per share from continuing operations of US$0.97, and a full-year 2025 net loss of US$177.04 million, or US$3.79 per share, both higher than the prior year. The sharp year-on-year increase in reported net loss highlights the cost of Celcuity’s ongoing development and commercialization efforts as it remains a pre-revenue, clinical-stage biotechnology company. With losses widening...
NasdaqGS:CWST
NasdaqGS:CWSTCommercial Services

A Look At Casella Waste Systems (CWST) Valuation After Recent Mixed Share Price Performance

Casella Waste Systems stock moves after recent share performance Casella Waste Systems (CWST) has caught investor attention after a mixed recent run, with the stock up around 10% over the past week but showing declines over the month and past 3 months. See our latest analysis for Casella Waste Systems. At a share price of $86.23, Casella’s recent 10% 7 day share price return contrasts with weaker 1 month and year to date share price returns. The 1 year total shareholder return of 17.11% and 5...
NasdaqGM:RYTM
NasdaqGM:RYTMBiotechs

Why Rhythm Pharmaceuticals (RYTM) Is Up 12.6% After EU IMCIVREE Expansion Boost and Board Refresh – And What's Next

Rhythm Pharmaceuticals recently received a positive opinion from the European Medicines Agency’s CHMP to expand IMCIVREE’s authorization to acquired hypothalamic obesity, and appointed veteran life sciences leader Kim Popovits to its Board, succeeding Ed Mathers. This combination of potential European label expansion for IMCIVREE and added commercialization expertise on the Board may meaningfully influence how Rhythm executes its rare neuroendocrine disease focus. Next, we’ll examine how the...
NYSE:LPX
NYSE:LPXForestry

Is It Too Late To Reassess Louisiana Pacific (LPX) After Recent Share Price Swings?

If you are wondering whether Louisiana-Pacific at around US$72 a share is offering good value or is already pricing in a lot of expectations, this article will help you frame that question using several valuation lenses. The stock has been choppy recently, with a 2.6% gain over the last 7 days, a 7.2% decline over 30 days, and year-to-date returns showing an 11.7% decline, while the 3-year and 5-year returns sit at 35.5% and 22.4% respectively. Recent attention on Louisiana-Pacific has...
NYSE:IBP
NYSE:IBPConsumer Durables

How Investors Are Reacting To IBP’s Earnings Beat, Weather-Hit Sales And Bigger Buyback Plan

Installed Building Products recently reported fourth-quarter earnings per share of US$3.24, beating expectations while revealing a 9% sales decline in its residential segment and announcing a new US$500 million share repurchase program alongside higher dividends. Management also reduced near-term revenue guidance and cited severe winter weather as a key factor pressuring residential insulation demand, even as commercial activity and acquisition efforts provided a partial offset. Next, we’ll...